Abstract
The strength of the effect of metaGRS 2 indicates that the GRS could potentially be used to 48 develop more efficient strategies for breast cancer screening for genotyped women. 49
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Background

52
Breast cancer (BC) is the most frequent cancer among women in the world, being also 53 the second leading cause of cancer death in women in more developed regions after lung 54 cancer 1 . As early diagnosis for BC could lead to successful treatment and good prognosis for 55 recovery, it is important to develop efficient risk prediction algorithms that aid to identify 56 high-risk individuals. Although many countries have implemented mammography screening 57 programs, they mostly apply to all women in certain age categories without any additional 58 stratification by other risk factors. However, the benefits of such screening programs are 59 often debated. Existing tools to assess BC risk 2-4 are often not systematically used in 60 screening due to insufficient up-to-date risk factor's information. Also, they only capture the 61 heritable component either in the form of family history or using the information on rare 62 genetic variants (BRCA1/2). 63
It has been estimated in twin studies that the heritability of breast cancer ranges from 64 20 to 30% 5 . However, only 5%-10% of BC cases have a strong inherited component 65 4 identified in a form of rare genetic variants 6 , indicating that in addition there should be a 66 considerable polygenic component in the disease liability. This is also supported by the 67 results of large genome-wide association studies (GWAS) -more than 100 genomic loci have 68 been identified as being associated with BC in Europeans 7 . 69
Based on the GWAS results, several efficient polygenic risk scores (GRS) have been 70 developed for common complex diseases that in many cases can be used to improve the 71 existing risk prediction algorithms [8] [9] [10] [11] . 14, 15 . Although several different GRSs have been proposed for BC risk 78 prediction, no head-to-head comparison of the scores has been found in the literature. It has 79 also not been assessed, whether the number of SNPs in the GRS could be increased. The 80 latter was also problematic due to unavailability of summary statistics from large-scale 81
GWASs. 82
In 2017, the large scale GWAS by Michailidou et al 7 released summary statistics for 83 around 11.8 million genetic variants. Almost at the same time, UK Biobank released their 84 GWAS results for BC for ~10.8 million SNPs. As evidence from studies on other common 85 complex diseases indicates that predictive ability of a GRS can improve by adding the effects 86 of a large number of independent SNPs in addition to the ones with established genome-wide 87 significance, we intend to explore this approach using both summary files. 88 5 More details about cohorts can be found in the Additional File 2 and overview of the 98 characteristics of the cohorts is given in the Additional File 1, Table S1 . 99
Methods
89
Study cohorts
Statistical Methods
100
General concept of Genetic Risk Scores (GRS) 101
The general definition of a GRS is based on the assumption that the polygenic 102 component of the trait (e.g. disease risk) can be approximated by a linear combination of In the present paper, we will compute two multigenic and two polygenic GRSs, 114 whereas the polygenic GRSs are developed using the PRSice software 19 . 115 GRSs, metaGRS 3 as the weighted average of three GRSs with the strongest 144 association with incident BC and finally metaGRS 2 based on top two predicting 145
GRSs. As weights to construct metaGRS, log(odds ratios) of GRSs from training set 146 from logistic regression model were used. 147
Finally, the UK biobank data was used to address the attenuation of GRS' effect while 148 accounting for family history of BC and to study associations between BC risk factors and 149
GRSs. While modelling in UK biobank, age at recruitment and 15 principal components are 150 included in the model. 151
Analysis of the GRS effects on incident BC 152 All 7 GRSs were evaluated in the analysis of incident BC in 30240 women from the 153
EstBB cohort who did not have an existing BC diagnosis at recruitment and were not 154 included in the case-control set used to select the best polygenic GRSs. Cox proportional 155 8 hazard models were used to estimate the crude and adjusted Hazard Ratios (HR) 156 corresponding to one standard deviation (SD) of the GRS. To properly account for left-157 truncation in the data, age of the participant was used as timescale in the analyses. To assess 158 the incremental value of GRSs when added to other known risk factors, the models were 159 additionally adjusted for the absolute risk estimates from the NCI Breast Cancer assessment 160 tool 2, 22 , based on age, race, age at menarche and age at first live birth of the participant. Other 161 possible risk factors such as number of biopsies were set as unknown. Harrell's c-statistic to 162 characterize the discriminative ability of each GRS and their incremental value compared to 163 NCI's Breast Cancer assessment tool absolute risk estimates alone were computed. Hazard 164 ratios for GRS top quintile and top 5% percentile compared to average and low GRS 165 categories were reported. Cumulative incidence estimates were computed with Aalen-166
Johansen estimator to account for competing risk. 167
Finally, associations between GRSs and variables related to female's reproductive 168 health and BC risk factors are explored using linear, logistic or Cox regression models 169 depending on the type of dependent variable in both EstBB and UKBB cohorts (more details 170 in the Additional File 2). 171
Results
172
GRSs association with prevalent breast cancer in OR = 1.34 (95% CI 1.18 to 1.52, p = 5.5*10 -6 ). Similar effect sizes for all four GRSs were 181 observed in the UKBB cohort (Table S2) . Detailed results on GRS-outcome associations in 182
EstBB with different p-value thresholds for SNP inclusion can be seen in Additional File 2, 183 Figure S1 . 184 As seen from Figure 1 , the cumulative BC incidence by the age of 70 is estimated to 220 be 12% (95% CI 7.7% to 16.3%) for women in the top 5% percentile of metaGRS 2 , 8.3% 221 (95% CI 5.6% to 11.0%) for those between 85%-95% percentiles and 7.4% (95% CI 4.85% 222 to 10.0%) for the women in 75%-85% percentiles. Cumulative BC incidence in the third, 223 second and first quartile of the metaGRS 2 distribution is estimated to be 5.8% (95% CI 4.4% 224 to 7.3%), 3.6% (95% CI 2.4% to 4.8%) and 2.4% (95% CI 1.4% to 3.3%), respectively. No 225 significant difference in BC hazard is seen between the two lowest quartiles (p = 0.26), with 226 both of them having considerably lower incidence level than the cohort average (overall 227 cumulative BC incidence estimated as 5.1% by the age of 70, 95% CI 4.5% to 5.8%). The correlations between seven scores varied between 0.3 to 1 (see Figure S2 ). While 236 dividing individuals into 2 categories ("non-high" -GRS < 95th percent and "high" -GRS in 237 14 top 5%) based on three GRSs (GRS UK, GRS ONCO or GRS 75 ), 87.7% (28547) of women were 238 assigned to non-high category with all three scores. However, 12.4% (4010) of women 239 belong to high category with at least one GRS. 0.33% (109) of women belonged to top 5% 240 with all three scores compared to ~10% (3240) of the women, who belonged into high 241 category only with one score (Figure 2) . 242
Association of incident breast cancer and GRSs
Associations of GRSs and other genetic and non-genetic predictors of
243 breast cancer
244
Both family history as well as GRSs were strongly associated with BC status in 245 UKBB, while the effects of GRSs were attenuated by less than 1% while adjusting for family 246 history (Additional File 1, Table S2 ). Known BC risk factors were only weakly associated 247 with in both UKBB and EstBB cohorts (Additional File 1, Table S3 -S4). BMI and waist 248 circumference were negatively associated with GRS UK in both EstBB and UKBB, the 249 association in EstBB was stronger for women under 50 years of age. Smoking status was 250 positively associated with all GRSs except GRS UK only in EstBB data. Age at menopause 251 was associated with some GRSs in both cohorts but the effects were in opposite direction. No 252 GRS showed association with any other type of cancer or overall mortality. 253
Discussion
254
We demonstrate that a metaGRS that combines a multigenic and a polygenic GRS for 255 breast cancer, metaGRS 2 , performs better than using either one of the previously published 256 multigenic GRSs and also better than the best polygenic GRS alone. While in average about 257 5% of women in the EstBB cohort (as well as in the Estonian population) have been 258 diagnosed with BC by the age of 70, women in the highest five percentiles of the 259 metaGRS 2 distribution have reached the same cumulative risk level (5%, 95% CI 2.1% to 260 7.8%) by the age of 49, thus more than 20 years earlier. It is also notable that women with 261 metaGRS 2 level below median reach such risk level (4.6%, 95% CI 3.6% to 5.6%) only by 262 age of 79, thus almost 10 years later. This finding suggests that the polygenic risk estimate 263 based on metaGRS 2 could be an efficient tool for risk stratification in clinical practice, for 264 targeted screening and prevention purposes. 265
Given that the potential benefits of non-selective BC screening within certain age 266 categories (compared to potential harm from over diagnosis) are under serious discussion in 267 medical community 23 , personalized approaches based on individual risk levels deserve 268 further assessment. Ideally, those should integrate available information from clinical risk 269 factors and also genetic information. The latter could include both moderate-and high-270 penetrance germline mutation testing, as well as polygenic risk scores. That approach is also 271 supported by our findings, where considerable increase in c-statistics were observed while 272 combining polygenic risk scores and NCI estimates together. 273
However, while incorporating a GRS in clinical BC prediction, one should keep in 274 mind that a GRS represents a mixture of different pathways, but is still not likely to capture 275 the heritable component completely. As our findings indicate that a GRS and family history 276 have independent predictive effects on BC risk, accounting for individual's genetic 277 information and family history simultaneously in risk estimation could be recommended. 278
As depending on a GWAS that is used as a basis, different (and not necessarily highly 279 correlated) GRSs can be produced, it is expected that those GRSs might emphasize the 280 effects of different biological pathways. This hypothesis seems plausible in the light of 281 several associations found between different GRSs and BC risk factors. 282
The fact that a metaGRS performs better than alternatives, suggests that the SNPs that 283 are included in the multigenic GRS 75 are potentially representing genetic pathways with 284 stronger effect on the disease risk and the combined score will give them a stronger weight 285 16 than the polygenic GRS alone. However, it also indicates that the SNPs included in the 286 polygenic GRS ONCO -but not in the GRS 75 -have some predictive power and therefore one 287
should not completely ignore them in an optimal GRS. 288
It remains an open question whether it is always the best practice to use metaGRS 289 instead of several different genetic risk scores -if one can pinpoint biological mechanisms 290 behind different scores, more optimal preventive strategies could be chosen. Still, until we are 291 unable to convincingly link different GRSs with specific preventive measures, targeted 292 prevention should be based on a GRS with the best possible overall predictive ability, such as 293 the metaGRS 2 proposed here. 294
One should also keep in mind that besides GRS there are genetic mutations such as 295 BRCA1/2 known to be associated with very high familiar BC risk. Therefore, in practice, any 296 genomic risk stratification should include search for high-risk genetic variants, or moderate 297 risk variants, as well, if possible. In the high-risk mutation carriers, the clinical management 298 could be based on the specific genetic (mendelian) variants, or if deemed useful in the future, 299 a combination of mendelian variants and GRS levels, but it definitely needs further studies. 300
Conclusions
301
In summary, our results show that an efficient polygenic risk estimate enables to 302 identify strata with more than four-fold differences in BC incidence. This definitely calls for 303 the development of personalized screening and prevention strategies that incorporate the GRS 304 information, having the potential to considerably increase the benefits of nation-wide 305 screening programs and reduce the existing controversies on their efficacy. However, one 306 should be aware of the fact that a GRS is not uniquely defined -as more research 307 accumulates, more efficient polygenic predictors could be developed that may re-categorize 308 some previously stratified individuals into high or low risk groups. In addition, a GRS should 309 
